Biblio Discovery — Demo Discovery Service

59 hasil

Menampilkan 1–20 · 1,69 detik · RSS

Jurnal

Blood Immunology & Cellular Therapy

ISSN 3050-5976 · Elsevier · 59 artikel di indeks

  1. Artikel Jurnal

    Reduced TCF-1 expression after hematopoietic cell transplantation restricts the T-cell response to vaccination

    Cheng Sheng Chai; Zahraa Al-Delfi; Eileen O. Santosa dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 4 · 2026 · Inggris · DOAJ

    Abstract: Vaccine immunogenicity is reduced after allogeneic hematopoietic stem cell transplantation (HSCT) and HSCT recipients experience high rates of SARS-CoV-2 breakthrough infection and severe disease. The underlying mechanisms are unclear. We conducted a prospective, longitudinal study of…

  2. Artikel Jurnal

    Tracking B-cell depletion and reconstitution using next-generation immunosequencing

    Lik Wee Lee; Rohaum Hamidi; Christina Baggott dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 4 · 2026 · Inggris · DOAJ

    Abstract: Monitoring B-cell depletion is essential for tracking the functional persistence of B-cell directed chimeric antigen receptor (CAR) T-cells. Although flow cytometry remains the standard of care, high-throughput immunosequencing, widely used for measurable residual disease (MRD)…

  3. Artikel Jurnal

    Referral variability and provider preparedness for pediatric sickle cell gene therapy: a national survey

    Cecile L. Karsenty; Anil George; Khaled Yassine dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Gene therapy (GT) has recently become available for sickle cell disease (SCD), but how it is being incorporated into pediatric clinical practice remains unclear. We conducted a national anonymous cross-sectional survey of board-certified or board-eligible pediatric hematology/oncology…

  4. Artikel Jurnal

    Accelerated step-up dosing of glofitamab in rapidly progressive R/R DLBCL: a real-world cohort analysis

    Fnu Amisha; Syeda Saba Kareem; Hanna Bailey dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Glofitamab, a CD20×CD3 bispecific T-cell engager, requires step-up dosing (SUD) to reduce cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Accelerated SUD shortens the time to target dose and may benefit patients with relapsed/refractory…

  5. Artikel Jurnal

    Acute myeloid leukemia cell therapy by combining MR1-modulating drugs and MR1 T cells

    Natalie Kehrer; Aisha Beshirova; Daniel Constantin dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: MR1-restricted T (MR1T) cells are a subset of unconventional T cells that recognize metabolite-derived antigens presented by the oligomorphic major histocompatibility complex class I–related molecule MR1. MR1T cells express a polyclonal T-cell receptor repertoire, can kill many tumor cell…

  6. Artikel Jurnal

    Real-world outcomes of glofitamab therapy in CAR-T–naïve patients with relapsed/refractory large B-cell lymphoma

    Liudmila Fedorova; Natalia Mikhailova; Kirill Lepik dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Glofitamab has demonstrated efficacy in patients with refractory diffuse large B-cell lymphoma (DLBCL). However, real-world data on glofitamab in other large B-cell lymphoma (LBCL) subtypes remain limited. This retrospective, multicenter study included 136 chimeric antigen receptor T…

  7. Artikel Jurnal

    B7-H3 expression affects outcomes in myeloma and is targetable with an NK cell engager

    Aimee M. Merino; Bartosz Grzywacz; Hayden Hamsher dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: B7-H3 acts as a checkpoint inhibitor, influences the tumor microenvironment, and is necessary for osteoclast (OC) development. Given its dual roles in promoting cancer survival and bone breakdown, we looked at its expression pattern in >200 patients with multiple myeloma (MM) and its…

  8. Artikel Jurnal

    Antigen levels in normal B cells and B-cell malignancies established by a multicolor quantitative flow cytometry assay

    Jay Y. Spiegel; Sheren Younes; Gary Gitana dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Antigen density on B cells may influence the efficacy of targeted therapies, yet current diagnostic tools, such as immunohistochemistry (IHC), offer limited quantitation. We developed a standardized, quantitative flow cytometry assay to assess CD19, CD20, and CD22 expression and established…

  9. Artikel Jurnal

    Preleukapheresis risk factors for BCMA CAR-T product manufacturing failure

    Samantha Sparrow; Allyson Wolcott; Sarah Mott dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: B-cell maturation antigen–directed chimeric antigen receptor T-cell therapies have transformed the treatment of relapsed/refractory multiple myeloma (MM). Manufacturing failures are a barrier to therapy delivery. Understanding modifiable risk factors of manufacturing failures could…

  10. Artikel Jurnal

    Cytoreduction with bridging therapy improves outcomes after CD19 CAR T-cell therapy in B-ALL with high disease burden

    Lindsey Murphy; Lanie Lindenfeld; Sitong Chen dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Patients with B-cell acute lymphoblastic leukemia (B-ALL) and high disease burden (DB; ≥5% marrow blasts and/or extramedullary disease) before lymphodepletion (LD) experience inferior survival and increased toxicity following CD19-directed chimeric antigen receptor (CAR) T-cell therapy…

  11. Artikel Jurnal

    Disparity in access to multiple myeloma CAR-T: a geospatial analysis of distance to CAR-T centers

    Michael Daunov; R. Benjamin Gorham; Olga Lytvynova dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Immune therapy with chimeric antigen receptor T cells (CAR-Ts) has greatly improved outcomes in patients with multiple myeloma (MM), promoting deep and durable remissions in heavily pretreated patients and moving closer to an elusive cure for this disease. Although CAR-T therapies hold…

  12. Artikel Jurnal

    Glucocorticoid-induced TNF receptor ligand–dependent B-cell expansion of regulatory T cells as an immune cell therapy strategy

    Cody J. Gurski; Mohamed Khalil; Kelli C. Sommers dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: B-cell–based immune cell therapies represent a potential strategy for restoring immune tolerance by expanding regulatory T cells (Tregs). CD4 + Foxp3 + Tregs are essential for maintaining immune homeostasis and represent an attractive therapeutic target. However, clinically established…

  13. Artikel Jurnal

    Immunological rationale for PD-1 blockade in intravascular large B-cell lymphoma harboring a

    Mika Takai; Kazuyuki Shimada; Kazuhiko Hayashi dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: The efficacy of immune checkpoint inhibitors (ICIs) in the treatment of malignant lymphomas has been limited to histological subtypes such as classic Hodgkin lymphoma, which frequently harbors genomic amplification of programmed death-ligand 1 ( PD-L1 ). Intravascular large B-cell…

  14. Artikel Jurnal

    BCMA-targeted T-cell engager therapy induces sustained remission in immune thrombocytopenia

    Michael Korenkov; Maximilian Rudolf Zuleeg; Julian Liebaert dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Immune thrombocytopenia (ITP) is an autoimmune disease mediated by platelet-reactive antibodies, leading to accelerated platelet clearance and an increased risk of bleeding. Despite multiple available therapeutic options, durable treatment-free remissions remain uncommon in patients with…

  15. Artikel Jurnal

    Outcomes of patients with primary refractory and early relapsing large B-cell lymphoma are inferior in the CD19 CAR T era

    Inna Y. Gong; Massimiliano Marinoni; Maria Azab dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Primary refractory disease (PRD) and early relapse are established adverse prognostic factors in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). In the contemporary era, it remains unclear whether time to relapse (TTR) continues to stratify risk across treatment lines, including…

  16. Artikel Jurnal

    Prospective cohort study of immunosuppression taper and discontinuation after allogeneic stem cell transplantation

    Abu-Sayeef Mirza; Jongphil Kim; Ram Thapa dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 3 · 2026 · Inggris · DOAJ

    Abstract: Patients tapering and discontinuing immunosuppression (IS) often develop graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT). We prospectively enrolled patients who received HCT at relevant time points, upon initiation of taper of the last systemic…

  17. Artikel Jurnal

    B-cell repertoire maturation as a biomarker for immune reconstitution after hematopoietic stem cell transplantation

    Yohei Funakoshi; Kimikazu Yakushijin; Sakuya Matsumoto dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 4 · 2026 · Inggris · DOAJ

    Abstract: A method for monitoring adaptive immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is not available. We developed the probability of generation (pGen)-somatic hypermutation (SHM) plot (pGen-SHM plot) to objectively monitor the long-term…

  18. Artikel Jurnal

    Brexucabtagene autoleucel consolidation in adult B-cell acute lymphoblastic leukemia: real-world efficacy and toxicity

    Nitin Jain; Niranjan Khaire; Nicholas Short dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 2 · 2026 · Inggris · DOAJ

    Abstract: Brexucabtagene autoleucel (brexu-cel), a CD19 chimeric antigen receptor (CAR) T cell is approved for patients with relapsed/refractory B-cell acute lymphoblastic leukemia. In the pivotal ZUMA-3 trial, patients were required to have >5% marrow blasts. We aimed to evaluate efficacy/toxicity…

  19. Artikel Jurnal

    Dosing patterns for talquetamab, including dose deescalation, in a real-world setting

    Rahul Banerjee; Ruibin Wang; Hsien-Yen Chang dkk.

    Blood Immunology & Cellular Therapy, Vol. 2 No. 2 · 2026 · Inggris · DOAJ

    Abstract: Talquetamab for relapsed/refractory multiple myeloma is initiated using step-up dosing (SUD) to mitigate cytokine release syndrome (CRS) and neurotoxicity (immune effector cell–associated neurotoxicity syndrome [ICANS]); both once-weekly and every 2 weeks dosing schedules are approved…